effect of methadone is 12~24 hours. Its major urinary excretion products are methadone, EDDP (2-ethylidene-1, 5-dimethyl-3, 3-diphenylprryolidine), and EMDP (2-ethyl-5-methy -3,

3-diphenylpyrrolidine).

Methadone Metabolite (EDDP)

EDDP(2-Ethylidine-1,5-dimethyl-3,3-diphenylpyrrolidine) is the primary metabolite of methadone. Methadone is a synthetic analgesic drug that is originally used in the treatment of narcotic addicts. The detection of EDDP is more beneficial than traditional methadone screening since EDDP exists only in urine from individuals that ingested methadone. The tampering of specimens by spiking the urine with methadone can be prevented. Secondly, renal clearance of EDDP is not affected by urinary pH, therefore the EDDP test provides a more accurate result of methadone ingestion than the methadone narent screen.

Methylenedioxymethamphetamine (MDMA) MDMA belongs to a family of man-made drugs. Its relatives include MDA (methylenedioxyamphetamine), and MDEA (methylenedioxyethylamphet amine). They all share the amphetamine-like effects. MDMA is a stimulant with hallucinogenic tendencies described as an empathogen as it releases mood-altering chemicals, such as cartooning and L-dopa, and may generate feelings of love and friendliness. The adverse effects of MDMA use include elevated blood pressure, hyperthermia, anxiety, paranoia and insomnia. MDMA is administered either by oral ingestion or intravenous injection. The effects of MDMA begin 30 minutes after intake, peak in an hour and last for 2~3 hours.

Morphine (MDP)

Morphine (MOP)

Opiate refers to any drug that is derived from the opium poppy, including the natural products, morphine and codeine, and the semi-synthetic drugs such as heroin. Opioid is

INSTRUCTIONS FOR USE

Test Dipcard

PLEASE READ ALL INFORMATION IN THE INSTRUCTIONS FOR USE BEFORE USING THE TEST!

REF See Box Label

This package insert applies to any combination of multi-drug tests and adulteration control tests. Therefore, some information on the performance characteristics of the product may not be relevant to your test. Please refer to the labels on the packaging and the prints on the test device to identify which drugs and adulteration controls are included in your test.

Multi-Drug Urine Test Dipcard is a rapid urine screening test. It's a lateral flow, one-step immunoassay for the qualitative detection of specific drugs and their principal metabolites in human urine at specified cut-off concentrations, with additional semi quantitative adulteration controls. The multi-drug test device can be combined with the adulteration controls such as Creatinine (CRE), Glutaraldehyde (GLU), Nitrite (NIT), pH, Specific Gravity (S.G.), and/or Oxidants/Pyridinium Chlorochromate (OXI/PCC), which is used for the determination of diluted or adulterated urine specimens. The adulteration control is an important pre-screening test for drug-testing.

Drug (Identifier)	Calibrator	Cut-off (ng/mL)
mphetamine (AMP 1000)	d-Amphetamine	1000
mphetamine (AMP 500)	d-Amphetamine	500
mphetamine (AMP 300)	d-Amphetamine	300
arbiturates (BAR 300)	Secobarbital	300
enzodiazepines (BZO 300)	Oxazepam	300
enzodiazepines (BZO 200)	Oxazepam	200
enzodiazepines (BZO 100)	Oxazepam	100
uprenorphine (BUP 10)	Buprenorphine	10
ocaine (COC 300)	Benzoylecgonine	300
ocaine (COC 150)	Benzoylecgonine	150
ocaine (COC 100)	Benzoylecgonine	100
annabinoids (THC 50)	11-nor-Δ9-THC-9-C00H	50
annabinoids (THC 40)	11-nor-Δ9-THC-9-C00H	40
annabinoids (THC 25)	11-nor-Δ9-THC-9-C00H	25
otinine (COT)	Cotinine	200
thyl Glucuronide (ETG)	Ethyl Glucuronide	500
entanyl (FTY 50)	Fentanyl	50
entanyl (FTY 20)	Fentanyl	20
abapentin (GAB)	Gabapentin	1000
etamine (KET 1000)	Ketamine	1000
etamine (KET 500)	Ketamine	500

ratom (KRA 250)	Mitragynine	250
ratom (KRA 100)	Mitragynine	100
ethamphetamine (MET 1000)	d-Methamphetamine	1000
ethamphetamine (MET 500)	d-Methamphetamine	500
ethamphetamine (MET 300)	d-Methamphetamine	300
ethadone (MTD 300)	Methadone	300
ethadone (MTD 200)	Methadone	200
ethadone Metabolite (EDDP 300)	2-ethylidene-1,5-dimethyl-3, 3-diphenylpyrrolidine (EDDP)	300
ethylenedioxymethamphetamine IDMA 500)	3,4-Methylenedioxymethamp- hetamine	500
ethylenedioxymethamphetamine MDMA 300)	3,4-Methylenedioxymethamp- hetamine	300
orphine (MOP 300)	Morphine	300
orphine (MOP 100)	Morphine	100
piate (OPI)	Morphine	2000
xycodone (OXY)	Oxycodone	100
hencyclidine (PCP)	Phencyclidine	25
ropoxyphene (PPX)	d-Propoxyphene	300
ynthetic Cannabis (K2 50)	JWH-018 / JWH-073	50
ynthetic Cannabis (K2 25)	JWH-018 / JWH-073	25
ynthetic Cannabis (K3)	AB-Pinaca	10
ricyclic Antidepressants (TCA)	Nortriptyline	1000
ramadol (TRA 1000)	Tramadol	1000
ramadol (TRA 200)	Tramadol	200
ramadol (TRA 100)	Tramadol	100
Monoacetylmorphine (6-MAM)	6-Monoacetylmorphine	10

Configurations of the Multi-Drug Urine Test Dipcard can consist of any combination of the above listed drug analytes but only one cutoff concentration under same drug condition will be included per device. It is intended for forensic use only.

This assay provides a qualitative, preliminary test result. A more specific analytical method must be used in order to obtain a confirmed result. Gas Chromatography/Mass spectrometry (GC/MS) or Liquid Chromatography/Tandem Mass Spectrometry (LC/MS-MS) are the preferred confirmatory methods. Professional judgment should be applied to any drug test result, particularly when preliminary positive results are indicated.

Amphetamine (AMP)
Amphetamine and the structurally related "designer" drugs are sympathomimetic amines whose biological effects include potent central nervous system (CNS) stimulation, anorectic, hyperthymic, and cardiovascular properties. They are usually taken orally, intravenously, or by smoking. Amphetamines are readily absorbed from the gastrointestinal tract and are then either deactivated by the liver or excreted unchanged in the urine. Methamphetamines inspartially metabolized to amphetamine and its major active metabolite. Amphetamines increase the heart rate and blood pressure, and suppress the appetite. Some studies indicate that heavy abuse may result in permanent damage to certain essential nerve structural in the brain. The effects of Amphetamines generally last 2~4 hours following use and the drug has a half-life of 4~24 hours in the body. About 30% of amphetamines are excreted in the urine in unchanged form, with the remainder as hydroxylated and deaminated derivatives. It can be detected in the urine for

1 to 2 days after use.

Amphetamine (AMP)

Barbiturates are central nervous system depressants. They are usually administered orally but are sometimes injected intramuscularly and intravenously. Barbiturates range from short-acting (approximately 15 minutes, such as secobarbital) to long-acting (24 hours or longer, such as Phenobarbital). Short-acting barbiturates are extensively metabolized in the body, while the long-acting ones are secreted primarily unchanged. Barbiturates produce alertness, wakefulness, increased energy, reduced hunger, and an overall feeling of well being. Large doses of Barbiturate could develop tolerance and physiological dependency and lead to its abuse.

physiological dependency and lead to its abuse.

Benzodiazepines (BZO)

Benzodiazepines are a class of drugs that are often therapeutically used as anxiolytics, anti-convulsants and sedative hypnotics. Benzodiazepines manifest their presence by analgesia, drowsiness, confusion, diminished reflexes, lowering of body temperature, respiratory depression, blockade of adrenocortical response, and a decrease in peripheral resistance without an impact on the cardiac index. The major pathways of elimination are the kidneys (urine) and the liver where it is conjugated to glucuronic acid. Large doses of Benzodiazepines could develop tolerances and physiological dependency and lead to its abuse. Only trace amounts (less than 1%) of Benzodiazepines are excreted unaltered in the urine, most of Benzodiazepines (nrine is conjugated drug. Oxazpam, a common metabolite of many benzodiazepines, remains detectable in urine for up to one week, which makes Oxazepam a useful marker of Benzodiazepines abuse.

week, which makes Oxazepam a useful marker of Benzodiazepines abuse.

Buprenorphine (BUP)

Buprenorphine is a potent analgesic often used in the treatment of opioid addiction. The drug is sold under the trade names Subutex*, Buprenex*, Temgesic* and Suboxone*, which contain Buprenorphine HCl alone or in combination with Naloxone HCl. Therapeutically, Buprenorphine is used as a substitution treatment for opioid addicts. Substitution treatment is a form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or identical substance to the drug normally used. In substitution therapy, Buprenorphine is as effective as Methadone but demonstrates a lower level of physical dependence. Concentrations of free Buprenorphine and Norbuprenorphine in urine may be less than 1 ng/ml after therapeutic administration, but can range up to 20 ng/ml in abuse situations. The plasma half-life of Buprenorphine is

2-4 hours. While complete elimination of a single dose of the drug can take as long as 6 days, the window of detection for the parent drug in urine is thought to be approximately days, the window of detection for the parent drug in urine is thought to be approximately 3 days. Substantial abuse of Buprenorphine has also been reported in many countries where various forms of the drug are available. The drug has been diverted from legitimate channels through theft, doctor shopping, and fraudulent prescriptions, and been abused via intravenous, sublingual, intranasal and inhalation routes.

Cocainie derived intom leaves of occapianii, sa potent central niervous system stimilaria and a local anesthetic. Among the psychological effects induced by using cocaine are euphoria, confidence and a sense of increased energy, accompanied by increased heart rate, dilation of the pupilis, fever, tremors and sweating. Cocaine is excreted in urine primarily as benzoylecgonine in a short period of time.

primarily as benzoylecgonine in a short period of time.

Cannabinoids (THC)

Cannabinoids is a hallucinogenic agent derived from the flowering portion of the hemp plant. The active ingredients in Cannabinoids, THC & Cannabinol can be metabolized and excreted as 11-nor-Δ9-tetrahydro cannabinol-9-carboxylic acid with a half-life of 24 hours. It can be detected for 1 to 5 days after use. Smoking is the primary method of use of Cannabinoids/cannabis. Higher doses used by abusers produce central nervous system effects, altered mood and sensory perceptions, loss of coordination, impaired short-term memory, anxiety, paranoia, depression, confusion, hallucinations and increased heart rate. A tolerance to the cardiac and psychotropic effects can occur, and withdrawal syndrome produces restlessness, insomnia, anorexia and nausea.

Cotinine (COT)

withdrawal syndrome produces restlessness, insomnia, anorexia and nausea.

Cotinine (COT)

Cotinine is the first-stage metabolite of nicotine, a toxic alkaloid that produces stimulation of the autonomic ganglia and central nervous system when in humans. Nicotine is a drug to which virtually every member of a tobacco-smoking society is exposed whether through direct contact or second-hand inhalation. In addition to tobacco, nicotine is also commercially available as the active ingredient in smoking replacement therapies such as nicotine gum, transdermal patches and nasal sprays. In a 24-hour urine, approximately 5% of a nicotine dose is excreted as unchanged drug with 10% as cotinine and 35% as hydroxycotinine; the concentrations of other metabolites are believed to account for less than 5%. While cotinine is thought to be an inactive metabolite, its elimination profile is more stable than that of nicotine which is largely urine pH dependent. As a result, cottinine is considered a good biological marker for determining nicotine use. The plasma half-life of nicotine is approximately 60 minutes following inhalation or parenteral administration. Nicotine and cotinine are rapidly eliminated by the kidney; the window of detection for cotinine in urine at a cutoff level of 200 ng/mL is expected to be up to 2-3 days after nicotine use.

200 ng/mL is expected to be up to 2-3 days after nicotine use.
Ethyl Glucuronide (ETG)
Ethyl Glucuronide (ETG) is a direct metabolite of alcohol. Presence in urine may be used to detect recent alcohol intake, even after alcohol is no longer measurable. Traditional laboratory methods detect the actual alcohol in the body, which reflects current intake within the past few hours (depending on how much was consumed). The presence of ETG in urine is a definitive indicator that it can be detected in the urine for 3 to 4 days after drinking alcohol, even alcohol is eliminated from the body. Therefore, ETG is a more accurate indicator of the recent intake of alcohol than measuring for the presence of alcohol itself. The ETG test can aid in the diagnosis of drunk driving and alcoholism, which has important significance in the forensic identification and medical examination.

Fentanyl (FTY) Fentanyl, belongs to powerful narcotics analgesics, and is a μ special opiates receptor stimulant. Fentanyl is one of the varieties that been listed in management of United Nations "Single Convention of narcotic drug in 1961". Among the opiates agents that under international control, fentanyl is one of the most commonly used to cure moderate to severe pain. After continuous injection of fentanyl, the sufferer will have the performance of protracted opioid abstinence syndrome, such as a taxia and irritability etc, which presents the addiction after taking fentanyl in a long time. Compared with drug addicts of amphetamine, drug addicts who take fentanyl mainly have got the possibility of higher infection rate of HIV, more dangerous injection behavior and more lifelong medication overdose.

Gabapentin is a medicine used to treat partial seizures, nerve pain from shingles and restless leg syndrome, and is in a class of medications called anticonvulsants. It works on the chemical messengers in the brain and nerves. Gabapentin may cause serious side effects such as drowsiness, dizziness, weakness, problems with balance or muscle movement, or increased seizures. Gabapentin can cause life-threatening breathing problems, especially if the users take gabapentin with drugs that cause severe sleepiness or decreased awareness. Some examples include narcotic opioids, anti-anxiety medicines, antidepressants, and antihistamines.

Ketamine (KET)
Ketamine (KET)
Ketamine was developed in the 1960s to replace phencyclidine (PCP) as an anesthetic agent and is most commonly used in veterinary medicine today. In addition to rohypnol (add hyperlink to page) and GHB, it is also considered a club drug, and may be used in drug-facilitated sexual assault situations. It is odorless, tasteless and usually swallowed in powder form or injected. Once taken, it is very short-acting and shows effects within minutes. Under federal law, ketamine is classified as a Schedule III drug, meaning it has approved medical use, but still possesses a high potential for abuse.

approved medical use, but still possesses a high potential for abuse.

Kratom (KRA)
Kratom is an herbal extract that comes from the leaves of an evergreen tree (Mitragyna speciosa) grown in Southeast Asia and Africa. Kratom extract is often marketed as a treatment for muscle pain, or to suppress appetite and stop cramps and diarrhea. Kratom is also sold as a treatment for panic attacks. At low doses, kratom acts as a stimulant, making users feel more energetic. At higher doses, it reduces pain and may bring on euphoria. At very high doses, it acts as a sedative, making users quiet and perhaps sleepy. In fact, kratom's potential for severe side effects outweigh its potential benefits, and in extreme cases, kratom has even caused death.

Methamphetamine (MFT)

Methamphetamine (MET)

Methamphetamine (MET)

Methamphetamine is a potent sympathomimetic agent with therapeutic applications. Acute higher doses lead to enhanced stimulation of the central nervous system and induce euphoria, alertness, and a sense of increased energy and power. More acute responses produce anxiety, paranoia, psychotic behavior, and cardiac dysrhythmias. The pattern of psychosis which may appear at half-life of about 15 hours is excreted in urine as amphetamine and oxidized as deaminated and hydroxylated derivatives. However, 40% of methamphetamine is excreted unchanged. Thus the presence of the parent compound in the urine indicates methamphetamine use.

Methadone (MTD) Methadone is a narcotic analgesic prescribed for the management of moderate to severe

products, morphine and codeine, and the semi-synthetic drugs such as heroin. Opioid is more general, referring to any drug that acts on the opioid receptor. Opioid analgesics comprise a large group of substances which control pain by depressing the central nervous system. Large doses of morphine can produce higher tolerance levels, physiological dependency in users, and may lead to substance abuse. Morphine is excreted unmetabolized, and is also the major metabolic product of codeine and heroin. Morphine is detectable in the urine for several days after an opiate dose. Opiate (OPI) Multi-Drug Urin

Oxycodone (OXY)

Oxycodone (OXY)
Oxycodone is an analgesic, which works by depressing the central nervous system. Oxycodone is abused for its opiate-like effects. In addition to its equal potency to morphine in analgesic effects, it is also equipotent to morphine in relieving abstinence symptoms from chronic opiate (heroin, morphine) use. For this reason, it is often used to alleviate or prevent the onset of opiate withdrawal by street users of heroin and methadone. The drug is most often administered orally. Like other opiates, Oxycodone can also depress the respiratory system resulting in suffocation and death when overdosed. Oxycodone is very addictive, both physically and psychologically. Some physical indications of Oxycodone abuse include extreme loss of appetite and weight, cramps, nausea, vomiting, excessive scratching and complaint of litching, excessive seating, constipation, pin-point pupils and watery eyes, reduced vision, drowsiness, euphoria, trance-like states, excessive thirst, tremors, twitching, irritability, hallucinations and lethargy.

Phencyclidine (PCP)

only known as PCP or "angel dust" is used primarily as recreationa Phencyclidine, commonly known as PCP or angle usus its used printing as recreased drug due to its hallucinogenic effects. It is generally self-administered by intravenous injection or by inhalation and concentrates fastest in fatly tissues and the brain. The effects of PCP are very much dose related. Small amounts of Phencyclidines (PCP) are central nervous system stimulants that produce alertness, wakefulness, increased central nervous system stimulants that produce alertness, wakefulness, increased energy, increased heat rate, and decreased sense of pain and touch, and an overall feeling of well being. Large doses of Phencyclidine (PCP) can result in death due to convulsions, heart and lung failure and coma. Large repeated doses of Phencyclidine (PCP) could develop tolerances and physiological dependency and lead to its abuse. PCP can be found in urine within 4 to 6 hours after use and will remain in urine for 7 to 14 days. Phencyclidine is excreted in the urine as an unchanged drug (4% to 19%) and conjugated metabolites (25% to 30%).

Propoxyphene (PPX) Propoxyphene (PPX) Propoxyphene is a prescription drug for the relief of pain. Overdose of propoxyphene can have the symptoms including analgesia, stupor, respiratory depression and coma. The half-life of propoxyphene is 8 to 24 hours. Propoxyphene reaches its peak in 1 to 2 hours after oral administration

Synthetic Cannabis (K2/K3)

Synthetic Cannabis (K2/K3)
Synthetic cannabis (K2/K3)
Synthetic cannabis is a psychoactive designer drug derived of natural herbs sprayed with synthetic chemicals that, when consumed, allegedly mimic the effects of cannabis, it is best known by the brand names K2 and Spice.
Synthetic cannabis act on the body in a similar way to cannabinoids naturally found in cannabis, such as THC. A large and complex variety of synthetic cannabis most often cannabicyclohexanol, JWH-018, JWH-073, or HU-210, are used in an attempt to avoid the laws that make cannabis illegal, making synthetic cannabis a designer drug. Although synthetic cannabis does not produce positive results in drug tests for cannabis, it is possible to detect its metabolites in human urine. The synthetic cannabinoids contained in synthetic cannabis products have been made illegal in many European countries. On November 24, 2010, the U.S. Drug Enforcement Administration announced it would use emergency powers to ban many synthetic cannabinoids within a month. As of March 1, 2011, five cannabinoids, JWH-018, JWH-073, CP-47,497, JWH-200, and cannabicyclohexanol are now illegal in the US.
AB-PINACA (K3 Spice) was synthesized by Pfeizer in 2009 for analgesic use. The drug gained popularity in Japan by 2012, and emerged in other countries by 2013. In under a year, AB-PINACA became one of the most commonly used drugs in the US. Synthetic marijuana is 1.5 times more potent than regular cannabis and is responsible for a number of hospitalizations and deaths as a result.

Tricyclic Antidepressants (TCA)

Tricyclic Antidepressants (TCA)

+75% Cutoff

+100% Cutoff

Tricyclic Antidepressants (TCA)
Tricyclic Antidepressants are a group of antidepressant drugs that are commonly used for treatment of depressive disorders. TCAs can be taken orally or by intramuscularly injection (IM). The symptoms of TCAs overdoses include agitation, confusion, hallucinations, hypertonicity, seizures, and EKG changes. The half-life of TCA varies from a few hours to several days. The commonly used TCAs are excreted with a very low percentage of unchanged drugs in the urine. Therefore, detection of the metabolites of TCAs in human urine has been used for screening the abuse of TCAs.

Tramadol (TRA)
Tramadol is a quasi-narcotic analgesic used in the treatment of moderate to severe pain.

It is a synthetic analog of codeine, but has a low binding affinity to the mu-opioid receptors. It has been for the treatment of diabetic neuropathy and restless leg syndrome. Large doses of Tramadol could develop tolerances and physiological dependency and lead to its abuse. Both Δ (d) and L forms of the isomers are controlled substances. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% is excreted as metabolites. The major pathways appear to be N- and O-demethylation, glucuronidation or sulfation in the liver.

6-Monoacetylmorphine (6-MAM) 6-Monoacetylmorphine (6-MAM) or 6-acetylmorphine (6-AM) is one of three active 6-MonoacetyImorphine (6-MAM) or 6-acetyImorphine (6-AM) is one of three active metabolites of heroin (diacetyImorphine), the others being morphine and the much less active 3-monoacetyImorphine (3-MAM). 6-MAM is rapidly created from heroin in the body, and then is either metabolized into morphine or excreted in the urine. 6-MAM remains in the urine for no more than 24 hours. So a urine specimen must be collected soon after the last heroin use, but the presence of 6-MAM guarantees that heroin was in fact used as recently as within the last day. 6-MAM is naturally found in the brain, but in such small quantities that detection of this compound in urine virtually guarantees that heroin has recently been consumed.

PRINCIPLE OF THE PROCEDURE

DRUGS-OF-ABUSE TESTS:

DRUGS-OF-ABUSE TESTS:

Multi-Drug Urine Test Dipcard is a competitive immunoassay that is used to screen for the presence of various drugs and drug metabolites in urine. It is chromatographic absorbent device in which, drugs within a urine sample, competitively combined to a limited number of drug monoclonal antibody (mouse) conjugate binding sites. When the test is activated, the urine is absorbed into each test strip by capillary action, mixes with the respective drug monoclonal antibody conjugate, and flows across a pre-coated membrane. When drug within the urine sample is below the detection level of the test, respective drug monoclonal antibody conjugate binds to the respective drug-protein conjugate immobilized in the Test Region (T) of the test strip. This produces a colored Test line in the Test Region (T) of the strip, which, regardless of its intensity, indicates a negative test result.

indicates a negative test result.

When sample drug levels are at or above the detection level of the test, the free drug in the sample binds to the respective drug monoclonal antibody conjugate, preventing the respective drug monoclonal antibody conjugate from binding to the respective drug-protein conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band in the test region, indicating a preliminary positive

To serve as a procedure control, a colored line will appear at the Control Region (C) of each strip, if the test has been performed properly.

Creatinine (CRE): Testing for sample dilution. In this assay, creatinine reacts with a Creatinine (CRE): Testing for sample dilution. In this assay, creatinine reacts with a creatinine indicator in an alkaline condition to form a purplish-brown color complex. The concentration of creatinine is directly proportional to the color intensity of the test pad. Glutaraldehyde (GLU): Testing for the presence of exogenous aldehyde. In this assay, the aldehyde group on the glutaraldehyde reacts with an indicator to form a pink/purple color

Nitrite (NIT): Testing for the presence of exogenous nitrite. Nitrite reacts with an aromatic amine to form a diazonium compound in an acid medium. The diazonium compound in turn couples with an indicator to produce a pink-red/purple color.

pH: Testing for the presence of acidic or alkaline adulterant. This test is based on the well-known double pH indicator method that gives distinguishable colors over wide pH range. The colors range from orange (low pH) to yellow and green to blue (high pH). Specific Gravity (S.G.): Testing for sample dilution. This test is based on the apparent pka change of certain pretreated polyelectrolytes in relation to the ionic concentration. In the presence of an indicator, the colors range from dark blue or blue-green in urine of low ionic concentration to green and yellow in urine of higher ionic concentration.

Oxidants/Pyridinium Chlorochromate (OXI/PCC): Tests for the presence of oxidizing eagents such as bleach and hydrogen peroxide. Pyridinium Chlorochromate commonly used adulterant. Normal human urine should not contain Oxidants or PCC.

- 1. For external use only. Do not swallow.
- 1. For exterial use only, Do Inc. swallow.
 2. Discard after first use. The test cannot be used more than once.
 3. Do not use the test device beyond expiry date.
 4. Do not use the test device if the pouch is punctured or not well sealed.
 5. Keep out of the reach of children.
 6. The used test dipcard should be discarded according to local regulations.

STORAGE AND STABILITY

1. Store at $35^{\circ}F$ - $86^{\circ}F$ (2°C - $30^{\circ}C)$ in the sealed pouch up to the expiration date. 2. DO NOT FREEZE.

DO NOT FREEZE. Keep away from direct sunlight, moisture and heat. Preferably open the pouch only shortly before the test

MATERIALS AND COMPONENTS REAGENTS AND MATERIALS SUPPLIED

- Adulteration Color Comparison Chart (If equipped)
- MATERIALS REQUIRED BUT NOT PROVIDED

Timer or stopwatch

SPECIMEN COLLECTION AND STORAGE


- 1. Collect urine specimen with a urine collection cup. Urine collected at any time of the
- 2. For best results, test the urine specimens immediately following coll 3. Urine specimens may be refrigerated at 35°F - 46°F / 2°C - 8°C and stored up to forty-eight hours. For longer storage, freeze the samples at 4°F / 20°C or below. Bring frager of refrigerated respines to remaining the performance remaining the remaining the

Remove the Multi-Drug Urine Test Dipcard from the sealed pouch and use it within the first hour after opening.
 Hold the one side of the device with one hand. Use the other hand to pull out the cap

- 3. Dip the absorbent end into the urine specimen for about 10 seconds. Make sure that the urine level does not touch the plastic device.
- 4. Start the timer.

 5. Re-cap and lay the device flat on a clean, dry, non-absorbent surface. 6. For the adulteration strip(s) if equipped: read results immediately, or at 30 seconds, or at 45 seconds and compare each adulterant pad to verify pad color is within acceptable range according to the Adulteration Color Comparison Chart. If the results indicate adulteration, do not read the drug test results. Instruct the donor to provide urine specimen again and retest using another new device.

7. For the drug tests: read the drug test results at 5 minutes. Do not read after 60



INTERPRETATION OF TEST RESULTS

ADULTERATION CONTROL: emi-quantitative results are obtained by visually comparing the color of each pad with the orresponding color blocks on the enclosed color chart.

Preliminary Positive (+)
A color band is visible in each control region (C). If no color band appears in the appr drug test region, a preliminary positive result is indicated for the corresponding drug specific test region.


Specific teat region.

Negative (-)

If a color band is visible in each control region (C) and the appropriate drug test region, it indicates that the concentration of the corresponding drug of that specific test region is absent or below the detection limit of the test.

invalid

If a color band is not visible in the control region (C) or a color band is only visible in the drug
test region, the test is invalid. Another test should be run to re-evaluate the specimen. Note: There is no meaning attributed to line color intensity or width. Any visible line is considered to be a line.



Users should follow the appropriate federal, state, and local guidelines concerning the frequency of assaying external quality control materials. Even though there is an internal procedural control line in the test device in the Control Region (C), the use of external controls is strongly recommended as good laboratory testing practice to confirm the test procedure and to verify proper test performance. Positive and negative controls should give the expected results. When testing the positive and negative controls, the same assay procedure should be adopted. External Control (positive and negative) should be run with each new lot, each new shipment and each new operator to determine that tests are working properly.

1. This test has been developed for testing urine samples only. No other fluids have been evaluated. DO NOT use this device to test substances other than urine.

2. There is a possibility that technical or procedural errors, as well as interfering substances in the urine specimen may cause incorrect results.

3. Contaminated urine samples may produce incorrect results. Strong oxidizing agents such as bleach (hypochlorite) can oxidize drug analyte. If a sample is suspected of contamination,

repeat the test with another urine sample.

4. This test is a qualitative screening assay. It is not designed to determine the quantitative concentration of drugs or the level of intoxication.

5. A positive result does not indicate level or intoxication, administration route or concentration in urine.

6. A negative result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cut-off level of the test.

ADULTERATION CONTROL:

Creatinine: Daily creatinine excretion, related to muscle mass of the human body, is usually

orstant. The DDT guideline states that urine specimens with creatinine levels of less than 20 mg/dl are indications of adulteration. Although these ranges are affected by age, sex, diet, muscle mass and local population distribution, sample with creatinine level of lower than 20 mg/dl should be considered adulterated. utaraldehyde: Glutaraldehyde is not a natural component of human urine and it should no

be present in normal urine. The presence of glutaraldehyde in the urine sample indicates the possibility of adulteration. However, false positive may result when ketone bodies are presence in urine. Ketone bodies may appear in urine when a person is in ketoacidosis, starvation or other metabolic abnormalities.

Nitrite: Although nitrite is not a normal component of urine, nitrite levels of up to 3.6 mg/dl may be found in some urine specimens due to urinary tract infections, bacterial contamination or improper storage. In this adulteration control, nitrite level above 7.5 mg/dl is pH: Normal urine pH ranges from 4.5 to 8.0. Values below pH 4.0 or above pH 9.0 are indicative of adultantian

phr. Normal unine pri langes inoin 4.5 to 3.0. Values below phr 4.0 or above phr 9.0 are indicative of adulteration.

Specific Gravity: Random urine may vary in specific gravity from 1.003-1.030. Normal adults with normal diets and normal fluid intake will have an average urine specific gravity of 1.016-1.022. Elevated urine specific gravity value may be obtained in the presence of moderate quantities of protein. DOT guidelines state that a urine specimen with specific gravity level of less than 1.003 is an indication of adulteration. Specific gravity and creatinine values should be considered together to provide a better picture of whether the sample is adulterated.

Oxidants: The presence of Bleach and other oxidizing reagents in the urine is indicative of adulteration since oxidizing reagents are not normal constituents of urine. Other oxidizing reagents include Hydrogen Peroxide, Ferricyanide, Persulfate, Pyridinium Chlorochromate...etc.

Pyridinium Chlorochromate: The presence of any chromate in urine is indicative of adulteration as chromate is not a normal constituent of urine.

A. Precision and Sensitivity

To investigate the precision and sensitivity, each drug samples were analyzed at the following concentrations: +100% cutoff, +75% cutoff, +50% cutoff, +25% cutoff, -25% cutoff, -50% cutoff, -75% cutoff and -100% cutoff. All concentrations were confirmed with GC-MS. The study was performed 2 runs /day and lasted 25 days using

three different lots of the corresponding drug of abuse test. Totally 3 operators articipated in the study of the corresponding drug of abuse test. Totally 3 operators tests 2 aliquots at each concentration for each lot per day (2 runs /day), for a total of 50 determinations per concentration per lot of the corresponding drug of abuse test.

Drug test	Approximate concentration	ntration Number of		Results pative/ Pos	itive
	of sample (ng/mL)	ns per lot	Lot 1	Lot 2	Lot
	+100% Cutoff	50	0/50	0/50	0/5
	+75% Cutoff	50	0/50	0/50	0/:
	+50% Cutoff	50	0/50	0/50	0/:
	+25% Cutoff	50	0/50	0/50	0/5
AMP 1000	Cutoff	50	13/37	14/36	13/
	-25% Cutoff	50	50/0	50/0	50.
	-50% Cutoff	50	50/0	50/0	50.
	-75% Cutoff	50	50/0	50/0	50.
	-100% Cutoff	50	50/0	50/0	50.
	+100% Cutoff	50	0/50	0/50	0/5
	+75% Cutoff	50	0/50	0/50	0/
	+50% Cutoff	50	0/50	0/50	0/
	+25% Cutoff	50	0/50	0/50	0/
AMP 500	Cutoff	50	12/38	12/38	12/
	-25% Cutoff	50	50/0	50/0	50.
	-50% Cutoff	50	50/0	50/0	50.
	-75% Cutoff	50	50/0	50/0	50.
	-100% Cutoff	50	50/0	50/0	50.
	+100% Cutoff	50	0/50	0/50	0/
	+75% Cutoff	50	0/50	0/50	0/
	+50% Cutoff	50	0/50	0/50	0/
	+25% Cutoff	50	0/50	0/50	0/
AMP 300	Cutoff	50	15/35	14/36	14/
	-25% Cutoff	50	50/0	50/0	50.
	-50% Cutoff	50	50/0	50/0	50.
	-75% Cutoff	50	50/0	50/0	50.
	-100% Cutoff	50	50/0	50/0	50

50 0/50 0/50 0/50

50 0/50 0/50 0/50 50 0/50 0/50 0/50

 Cutoff
 50
 12/38
 13/37
 13/37

 -25% Cutoff
 50
 50/0
 50/0
 50/0

 -50% Cutoff
 50
 50/0
 50/0
 50/0

50 0/50 0/50 0/50 50 0/50 0/50 0/50 +25% Cutoff 50 0/50 0/50 50 14/36 12/38 14/36 -25% Cutoff 50 50/0 50/0 50/0 -50% Cutoff 50 50/0 50/0 -75% Cutoff 50 50/0 50/0 -100% Cutoff 50 50/0 50/0 50/0 +100% Cutoff 50 0/50 0/50 0/50 +75% Cutoff 50 0/50 0/50 0/50 0/50 0/50 +25% Cutoff 50/0 50/0 -25% Cutoff -75% Cutoff -100% Cutoff 50 50/0 50/0 50/0 +100% Cutoff 50 0/50 0/50 0/50 +75% Cutoff 50 0/50 0/50 0/50 +50% Cutoff 50 0/50 0/50 0/50 0/50 +25% Cutoff -25% Cutoff 50/0 50/0 -75% Cutoff

BZO 100	-75% Cutoff	50	50/0	50/0	50/0
BZO 100	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
BUP 10	Cutoff	50	16/34	15/35	15/35
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
COC 300	Cutoff	50	12/38	13/37	12/38
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
COC 150	Cutoff	50	15/35	14/36	14/36
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
COC 100	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
	Cutoff	50	14/36	14/36	14/36

	-25% Cutoff	50	50/0	50/0	50/0
OC 100	-50% Cutoff	50	50/0	50/0	50/0
00 100	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
HC 50	Cutoff	50	14/36	13/37	14/36
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
HC 40	Cutoff	50	14/36	13/37	12/38
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
HC 25	Cutoff	50	12/38	11/39	12/38
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
OT 200	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50

		1			
	+25% Cutoff	50	0/50	0/50	0/50
	Cutoff	50	13/37	13/37	13/37
COT 200	-25% Cutoff	50	50/0	50/0	50/0
001 200	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
ETG 500	Cutoff	50	13/37	13/37	14/36
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
•	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
FTY 50	Cutoff	50	13/37	14/36	13/37
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
FTY 20	Cutoff	50	12/38	12/38	13/37
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
GAB 1000	+100% Cutoff	50	0/50	0/50	0/50
GAB 1000	+100% Cutoff	50	0/50	0/50	

	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
OAD 1000	Cutoff	50	13/37	12/38	11/39
GAB 1000	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
KET 1000	Cutoff	50	12/38	11/38	12/38
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
KET 500	Cutoff	50	13/37	12/38	12/38
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
KDV 3EC	+25% Cutoff	50	0/50	0/50	0/50
KRA 250	Cutoff	50	14/36	12/38	12/38
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0

KRA 250	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
KRA 100	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
	Cutoff	50	12/38	12/38	13/37
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
MET 1000	Cutoff	50	11/39	10/40	11/39
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
MET 500	Cutoff	50	12/38	13/37	12/38
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
METOOC	+50% Cutoff	50	0/50	0/50	0/50
MET 300	+25% Cutoff	50	0/50	0/50	0/50
	Cutoff	50	12/38	13/37	13/37
	-25% Cutoff	50	50/0	50/0	50/0

	-50% Cutoff	50	50/0	50/0	50/0
MET 300	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
MTD 300	Cutoff	50	14/36	15/35	14/36
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
MTD 200	Cutoff	50	15/35	14/36	14/36
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
EDDP 300	Cutoff	50	13/37	12/38	12/38
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
MDMV EUU	+75% Cutoff	50	0/50	0/50	0/50
MDMA 500	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
	·				
		20			

	Cutoff	50	10/40	10/40	11/39
	-25% Cutoff	50	50/0	50/0	50/0
MDMA 500	-50% Cutoff	50	50/0	50/0	50/0
ľ	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
MDMA 300	Cutoff	50	11/39	11/39	10/40
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
MOP 300	Cutoff	50	14/36	15/35	14/36
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
MOP 100	Cutoff	50	15/35	15/35	15/35
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
0.01.0000	+100% Cutoff	50	0/50	0/50	0/50
OPI 2000	+75% Cutoff	50	0/50	0/50	0/50
		21			

	+50% Cutoff	50	0/50	0/50	0/5
	+25% Cutoff	50	0/50	0/50	0/5
	Cutoff	50	10/40	9/41	10/4
OPI 2000	-25% Cutoff	50	50/0	50/0	50/
	-50% Cutoff	50	50/0	50/0	50/
	-75% Cutoff	50	50/0	50/0	50/
	-100% Cutoff	50	50/0	50/0	50/
	+100% Cutoff	50	0/50	0/50	0/5
	+75% Cutoff	50	0/50	0/50	0/5
	+50% Cutoff	50	0/50	0/50	0/5
	+25% Cutoff	50	0/50	0/50	0/5
OXY 100	Cutoff	50	13/37	15/35	15/3
	-25% Cutoff	50	50/0	50/0	50/
	-50% Cutoff	50	50/0	50/0	50/
	-75% Cutoff	50	50/0	50/0	50/
	-100% Cutoff	50	50/0	50/0	50/
	+100% Cutoff	50	0/50	0/50	0/5
	+75% Cutoff	50	0/50	0/50	0/5
	+50% Cutoff	50	0/50	0/50	0/5
	+25% Cutoff	50	0/50	0/50	0/5
PCP 25	Cutoff	50	15/35	16/34	14/3
	-25% Cutoff	50	50/0	50/0	50/
	-50% Cutoff	50	50/0	50/0	50/
	-75% Cutoff	50	50/0	50/0	50/
	-100% Cutoff	50	50/0	50/0	50/
	+100% Cutoff	50	0/50	0/50	0/5
	+75% Cutoff	50	0/50	0/50	0/5
	+50% Cutoff	50	0/50	0/50	0/5
	+25% Cutoff	50	0/50	0/50	0/5
PPX 300	Cutoff	50	12/38	12/38	12/3
	-25% Cutoff	50	50/0	50/0	50/
	-50% Cutoff	50	50/0	50/0	50/
	-75% Cutoff	50	50/0	50/0	50/
	-100% Cutoff	50	50/0	50/0	50/
		22			

	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
İ	+25% Cutoff	50	0/50	0/50	0/50
(50)	Cutoff	50	13/37	13/37	13/37
	-25% Cutoff	50	50/0	50/0	50/0
Ī	-50% Cutoff	50	50/0	50/0	50/0
Ī	-75% Cutoff	50	50/0	50/0	50/0
Ī	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
Ī	+25% Cutoff	50	0/50	0/50	0/50
(25)	Cutoff	50	15/35	15/35	14/36
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
(10)	Cutoff	50	13/37	14/36	14/36
[-25% Cutoff	50	50/0	50/0	50/0
[-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
[+50% Cutoff	50	0/50	0/50	0/50
1000	+25% Cutoff	50	0/50	0/50	0/50
	Cutoff	50	12/38	11/39	11/39
[-25% Cutoff	50	50/0	50/0	50/0
1	-50% Cutoff	50	50/0	50/0	50/0

TCA 1000	-75% Cutoff	50	50/0	50/0	50/0
TCA 1000	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
TRA 1000	Cutoff	50	14/36	13/37	13/37
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
TRA 200	Cutoff	50	13/37	13/37	13/37
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
Ī	+75% Cutoff	50	0/50	0/50	0/50
	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
TRA 100	Cutoff	50	14/36	13/37	14/36
	-25% Cutoff	50	50/0	50/0	50/0
	-50% Cutoff	50	50/0	50/0	50/0
	-75% Cutoff	50	50/0	50/0	50/0
	-100% Cutoff	50	50/0	50/0	50/0
	+100% Cutoff	50	0/50	0/50	0/50
	+75% Cutoff	50	0/50	0/50	0/50
6-MAM 10	+50% Cutoff	50	0/50	0/50	0/50
	+25% Cutoff	50	0/50	0/50	0/50
	Cutoff	50	14/36	15/35	15/35

}	-25% Cutoff	50		50/0	50/0	50/0
6-MAM 10	-50% Cutoff	50		50/0	50/0	50/0
	-75% Cutoff	50		50/0	50/0	50/0
	-100% Cutoff	50		50/0	50/0	50/0
e following to	d Cross-reactivity able lists the concentrest Dipcard identified		result		time of 5 n	
Amphetamine	(AMP 1000)				\ J. /	
d-Amphetamii			1,00	0		
d/l-Amphetam	nine		3,00	0		
-Amphetamin	е		50,0	00		
	enedioxyamphetamine (I	MDA)	5,00	0		
Phentermine			3,00	0		
Hydroxyamph	etamine		10,0	00		
d-Methamphe	tamine		>100	0,000		
-Methamphet				0,000		
	nedioxyethylamphetamir			0,000		-
	nedioxymethamphetami	ne (MDMA)		0,000		
(1R,2S)-(-)-Eph				0,000		
β-Phenylethylamine		100,				
Tryptamine		100,				
p-Hydroxynorephedrine		100,				
Phenylpropanolamine			0,000			
(±)Phenylpropanolamine			0,000			
p-Hydroxyamphetamine		100,				
d/l-Norephedrine Benzphetamine		100,	000			
-Epinephrine	IC			0.000		
d/l-Epinephrin	Δ		>100,000			
и/ г-срптерппп	С		-100	3,000		
Amphetamine						
d-Amphetamii			500			
d/l-Amphetamine		1,50				
l-Amphetamine		25,0				
(+/-) 3,4-methylenedioxyamphetamine (MDA)		2,50				
Phentermine		1,50				
Hydroxyamphetamine		5,00				
d-Methamphe				0,000		
l-Methamphetamine		(LIDEL)		0,000		
(+/-)3,4-Methylenedioxyethylamphetamine (MDEA)			>100	0,000		

0,000 0,000
000 000 000 0,000 0,000 0,000 000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000
000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000
0,000 0,000 000 000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000
0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000
000 000 0,000 0,000 0,000 0,000 0 0 0 0 0 0 0 0 0 0 0 0
000 0,000 0,000 0,000 0,000 00 00 00 00
0,000 0,000 0,000 000 00 00 00 00 00 00
0,000 0,000 00 00 0,000 0,000 0,000 0,000 0,000 0,000
0,000 00 00 0,000 0,000 0,000 0,000 0,000 0,000
000 00 00 00,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000
000 00 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000
000 00 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000
000 00 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000
000 0 0 0,000 0,000 0,000 0,000 0,000 0,000 0,000
0 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000
0 0,000 0,000 0,000 0,000 0,000 0,000 0,000 0,000
00 0,000 0,000 0,000 0,000 0,000 0,000 0,000
0,000 0,000 0,000 0,000 0,000 0,000 0,000
0,000 0,000 0,000 0,000 0,000 0,000 0,000
0,000 0,000 0,000 0,000 0,000 0,000
0,000 0,000 ,000 ,000
0,000 0,000 ,000 ,000
0,000 ,000 ,000
,000 ,000
,000
0,000
0,000
,000
,000
0,000
0,000
0,000
-,
10
0
)

Butethal	500	
Cyclopentobarbital	500	
Pentobarbital	200	
Phenobarbital	300	
. (270 000)		
Benzodiazepines (BZO 300)		
Oxazepam	300	
Alprazolam	150	
α-Hydroxyalprazolam	1,500	
Bromazepam	100	
Chlordiazepoxide	500	
Clobazam	750	
Clonazepam	1,500	
Clorazepate dipotassium	100	
Diazepam	500	
Estazolam	500	-
Flunitrazepam	2,500	
Midazolam	2,000	
Nitrazepam	2,000	
Nordiazepam	500	
Temazepam	250	
Triazolam	1,000	
Desalkylflurazepam	500	
Lorazepam	5,000	
Norchlordiazepoxide	500	
Nordazepam	1,000	
Delorazepam	2,000	
Demoxepam	5,000	
Flurazepam	500	
Benzodiazepines (BZO 200)		
Oxazepam	200	
Alprazolam	100	
α-Hydroxyalprazolam	1,000	
Bromazepam	75	
Chlordiazepoxide	500	
Clobazam	500	
Clonazepam	1,000	
Clorazepate dipotassium	75	
Diazepam	500	
Estazolam	500	
Flunitrazepam	2,000	-
Midazolam	1,000	

Nitrazepam	1,000
Nordiazepam	500
Temazepam	200
Triazolam	750
Desalkylflurazepam	500
Lorazepam	4,000
Norchlordiazepoxide	500
Nordazepam	750
Delorazepam	1,000
Demoxepam	4,000
Flurazepam	500
Paradianarina (P70 100)	
Benzodiazepines (BZO 100) Oxazepam	100
Alprazolam	50
	500
α-Hydroxyalprazolam Bromazepam	50
Chlordiazepoxide	300
Clobazam	250
	500
Clonazepam Clorazepate dipotassium	50
Diazepam	300
Estazolam	300
Flunitrazepam	1,000
Midazolam	500
Nitrazepam	500
Nordiazepam	300
Temazepam	150
Triazepani	500
	300
Desalkylflurazepam Lorazepam	2,500
Norchlordiazepoxide	300
Nordazepam	500
Delorazepam	500
Demoxepam	2,500
Flurazepam	300
riuiazepaiii] 300
Buprenorphine (BUP 10)	
Buprenorphine	10
Norbuprenorphine	50
Buprenorphine 3-D-glucuronide	10
Norbuprenorphine 3-D-glucuronide	10

Oxymorphone	>100,000
Hydromorphone	>100,000
Cocaine (COC 300)	
Benzoylecgonine	300
Cocaine HCl	750
Cocaethylene	12,500
Ecgonine	30,000
Ecgonine methyl ester	>100,000
Norcocaine	>100,000
Cocaine (COC 150)	
Benzoylecgonine	150
Cocaine HCl	500
Cocaethylene	5,000
Ecgonine	15,000
Ecgonine methyl ester	>100,000
Norcocaine	>100,000
Cocaine (COC 100)	
Benzoylecgonine	100
Cocaine HCl	250
Cocaethylene	2,500
Ecgonine	5,000
Ecgonine methyl ester	>100,000
Norcocaine	>100,000
Cannabinoids (THC 50)	
11-nor-∆9-THC-9-COOH	50
11-nor-∆8-THC-9-COOH	30
(±)-11-Hydroxy-Δ9-THC	2,500
Δ8- Tetrahydrocannabinol	2,000
Δ9- Tetrahydrocannabinol	5,000
Cannabinol	10,000
Cannabidiol (CBD)	100,000
(±)-11-nor-9-carboxy-Δ 9-THC	100
11-nor-∆9-THC-carboxy glucuronide	100
	<u> </u>
Cannabinoids (THC 40)	
11-nor-Δ9-THC-9-COOH	40
	30
11-nor-Δ8-THC-9-COOH (±)-11-Hydroxy-Δ9-THC	

4,000 10,000 100,000 100
100,000
100
100
25
15
1,250
1,000
2,500
5,000
75,000
50
75
200
500
>100,000
>100,000
>100,000
>100,000
50
150
500
>10,000
>10,000
>10,000
20
50
150
>10,000
>10,000

Cohonomin (CAD)		
Gabapentin (GAB)	1 1000	
Gabapentin	75.000	
Pregabalin		
Vigabatrin	>100,000	
Salicylic acid	>100,000	
Valproic acid	>100,000	
Ketamine (KET 1000)		
Ketamine	1,000	
2-Fluorodeschloroketamine	2,000	
Methadone	50,000	
Pethidine	12,500	
Methylamphetamine	12,500	
Methoxyphenamine	12,500	
Promethazine	25,000	
Phencyclidine	25,000	
Ketamine (KET 500)		
Ketamine	500	
2-Fluorodeschloroketamine	1.000	
Methadone	25.000	
Pethidine	7,500	
Methylamphetamine	7,500	
Methoxyphenamine	7,500	
Promethazine	12.500	
Phencyclidine	12,500	
Kratom (KRA 250)		
Mitragynine	250	
7-Hydroxymitragynine	500	
Kratom (KRA 100)		
Mitragynine	100	
7-Hydroxymitragynine	150	
Methamphetamine (MET 1000)		
d-Methamphetamine	1.000	
d-Amphetamine	50,000	
Chloroquine	50,000	
(1R,2S)-(-)-Ephedrine		
(11,20)-(7)-Epiteurine	50,000	

(-)-Methamphetamine	25,000
(+/-)3,4-Methylenedioxumethamphetamine (MDMA)	4.000
β-Phenylethylamine	50,000
Trimethobenzamide	10.000
I-Amphetamine	75,000
(+/-)3,4-Methylenedioxyethylamphetamine (MDEA)	30,000
Mephentermine	50,000
Methoxyphenamine	50,000
Fenfluramine	75,000
Procaine	>100,000
d/l-Amphetamine	>100,000
p-Hydroxymethamphetamine	30,000
I-Phenylephrine	>100,000
d/l-Methamphetamine	1,000
(+/-) 3,4-Methylenedioxyamphetamine(MDA)	>100,000
	-
Methamphetamine (MET 500)	
d-Methamphetamine	500
d-Amphetamine	25,000
Chloroquine	25,000
(1R,2S)-(-)-Ephedrine	25,000
(-)-Methamphetamine	12,500
(+/-)3,4-Methylenedioxumethamphetamine (MDMA)	2,000
β-Phenylethylamine	25,000
Trimethobenzamide	5,000
I-Amphetamine	50,000
(+/-)3,4-Methylenedioxyethylamphetamine (MDEA)	15,000
Mephentermine	25,000
Methoxyphenamine	25,000
Fenfluramine	37,500
Procaine	>100,000
d/l-Amphetamine	75,000
p-Hydroxymethamphetamine	15,000
I-Phenylephrine	>100,000
d/l-Methamphetamine	500
(+/-) 3,4-Methylenedioxyamphetamine(MDA)	75,000
Methamphetamine (MET 300)	
d-Methamphetamine	300
d-Amphetamine	12,500
Chloroquine	12,500
(1R,2S)-(-)-Ephedrine	12,500
(-)-Methamphetamine	7,500

(+/-)3,4-Methylenedioxumethamphetamine (MDMA)	2,000
β-Phenylethylamine	15,000
Trimethobenzamide	4,000
I-Amphetamine	40,000
(+/-)3,4-Methylenedioxyethylamphetamine (MDEA)	10,000
Mephentermine	15,000
Methoxyphenamine	15,000
Fenfluramine	25,000
Procaine	>100.000
d/l-Amphetamine	50,000
p-Hydroxymethamphetamine	10,000
I-Phenylephrine	>100,000
d,l-Methamphetamine	500
(+/-) 3,4-Methylenedioxyamphetamine (MDA)	50.000
(, , , =,	50,000
Methadone (MTD 300)	
Methadone	300
FDDP	>100,000
Doxylamine	50.000
Levacetylmethadol (LAAM)	>100.000
EMDP	>100,000
Alpha Methadol	>100,000
	100,000
Methadone (MTD 200)	
Methadone	200
EDDP	>100.000
Doxylamine	37.500
Levacetylmethadol (LAAM)	>100.000
EMDP	>100,000
Alpha Methadol	>100.000
Methadone Metabolite (EDDP)	
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine	300
Methadone	>100,000
EMDP	>100.000
Doxylamine	>100,000
Levacetylmethadol (LAAM)	>100,000
Disopyramide	>100,000
Alpha Methadol	>100,000
Methylenedioxymethamphetamine (MDMA 5	00)
3,4-Methylenedioxymethamphetamine (MDMA)	500
	3.000
3,4-Methylenedioxyamphetamine HCl (MDA)	

3,4-Methylenedioxyethylamphetamine (MDEA)	300
d-Methamphetamine	>100,000
d-Amphetamine	>100,000
l-Methamphetamine	>100,000
l-Amphetamine	>100,000
Methylenedioxymethamphetamine (MDMA	300)
3,4-Methylenedioxymethamphetamine (MDMA)	300
3,4-Methylenedioxyamphetamine HCI (MDA)	2,000
3,4-Methylenedioxyethylamphetamine (MDEA)	200
d-Methamphetamine	>100,000
d-Amphetamine	>100,000
l-Methamphetamine	>100,000
l-Amphetamine	>100,000
Morphine (MOP 300)	
Morphine	300
Codeine	300
Hydrocodone	5,000
Hydromorphone	1,000
6-Monoacetylmorphine	150
Morphine 3-β-D-glucuronide	1,000
Ethylmorphine	100
Diacetylmorphine (heroin)	300
Levorphanol	10,000
Norcodeine	5,000
Oxycodone	75,000
Thebaine	3,000
Normorphine	3,000
Oxymorphone	25,000
Procaine	>100,000
Codeine-6-β-D-glucuronide	500
d-Norpropoxyphene hydrochloride	300
Morphine (MOP 100)	
Morphine	100
Codeine	100
Hydrocodone	2,000
Hydromorphone	500
6-Monoacetylmorphine	75
Morphine 3-β-D-glucuronide	500
Ethylmorphine	50
Diacetylmorphine (heroin)	100

Levorphanol	5,000	
Norcodeine	2,000	
Oxycodone	25,000	
Thebaine	1,000	
Normorphine	1,000	
Oxymorphone	10,000	
Procaine	>100,000	
Codeine-6-β-D-glucuronide	200	
d-Norpropoxyphene hydrochloride	100	
Opiate (OPI)		
Morphine	2,000	
Codeine	2,000	
Hydrocodone	12,500	
Hydromorphone	5,000	
6-Monoacetylmorphine	1,500	
Morphine 3-β-D-glucuronide	2,000	
Ethylmorphine	1,500	
Diacetylmorphine (heroin)	2,000	
Levorphanol	75,000	
Norcodeine	12,500	
Oxycodone	>100,000	
Thebaine	5.000	
Normorphine	50.000	
Oxymorphone	>100,000	
Procaine	>100.000	
Codeine-6-β-D-glucuronide	3,000	
d-Norpropoxyphene hydrochloride	5,000	
Oxycodone (OXY)	100	
Oxycodone	100	
Hydrocodone	5,000	
Hydromorphone Oxymorphone	50,000	
Codeine	1,000	
Ethylmorphine	>100,000	
	>100,000	
Dihydrocodeine	20,000	
Oxymorphone-3β-D-glucuronide	5,000	
Morphine	>100,000	
6-Monoacetylmorphine Buprenorphine	>100,000	
Thebains	>100,000	

4-Hydroxy Phencyclidine	1,500
Propoxyphene (PPX)	
d-Propoxyphene	300
d-Norpropoxyphene	300
а ттогргорохурпено	1 000
Synthetic Cannabis (K2 50)	
JWH-018 Pentanoic Acid	50
JWH-073 Butanoic Acid	50
JWH-018 N-4-hydroxypentyl	2,000
JWH-018 (Spice Cannabinoid)	1,000
JWH-018 4-Hydroxypentyl metabolite-D5 (indole-D5)	1,000
JWH-073 (Spice Cannabinoid)	2,000
JWH-073 3-Hydroxybutyl metabolite	1,000
JWH-073 3-Hydroxybutyl metabolite-D5 (indole-D5)	1,000
JWH-019 6-hydroxypentyl	1,000
JWH-122 N-4-hydroxypentyl	2,000
JWH-210 5-Hydroxypentyl metabolite	5.000
AM2201 4-Hydroxypentyl metabolite	1,000
JWH-018 N-4-hydroxypentyl	2,000
JWH-018 (Spice Cannabinoid)	1,000
JWH-018 4-Hydroxypentyl metabolite-D5 (indole-D5)	1,000
Synthetic Cannabis (K2 25)	
JWH-018 Pentanoic Acid	25
JWH-073 Butanoic Acid	25
JWH-018 N-4-hydroxypentyl	1,000
JWH-018 (Spice Cannabinoid)	500
JWH-018 4-Hydroxypentyl metabolite-D5 (indole-D5)	500
JWH-073 (Spice Cannabinoid)	1,000
JWH-073 3-Hydroxybutyl metabolite	500
JWH-073 3-Hydroxybutyl metabolite-D5 (indole-D5)	500
JWH-019 6-hydroxypentyl	500
JWH-122 N-4-hydroxypentyl	1,000
JWH-210 5-Hydroxypentyl metabolite	2,500
AM2201 4-Hydroxypentyl metabolite	500
JWH-018 N-4-hydroxypentyl	1,000
JWH-018 (Spice Cannabinoid)	500
JWH-018 4-Hydroxypentyl metabolite-D5 (indole-D5)	500
Synthetic Cannabis (K3 10)	
AB-Pinaca	

Phencyclidine (PCP)
Phencyclidine

AB-Pinaca 4-Hydroxypentyl metabolite	10
AB-Pinaca 5-Pentanoic acid metabolite	10
AB-Fubinaca	12
ADB-Fubinaca	15
ADBICA	20
AB-CHMINACA	15
MAB-CHMINACA	10
Tricyclic Antidepressants (TCA)	
Nortriptyline	1,000
Nordoxepin	1,000
Trimipramine	3,000
Promazine	1,500
Desipramine	200
Imipramine	750
Clomipramine	10,000
Doxepin	1,250
Maprotiline	2,000
Amitriptyline	1,500
Promethazine	25,000
Cyclobenzaprine	1,000
Norclomipramine	12,500
Tramadol (TRA 1000)	
Tramadol	1.000
(+/-) Chlorpheniramine	>1,000
Diphenhydramine	>100,000
Pheniramine	>100,000
PCM	>100,000
FCIVI	>100,000
Tramadol (TRA 200)	
Tramadol	200
(+/-) Chlorpheniramine	>100,000
Diphenhydramine	>100,000
Pheniramine	>100,000
PCM	>100,000
Tramadol (TRA 100)	
Tramadol	100
(+/-) Chlorpheniramine	>100,000
Diphenhydramine	>100,000
Pheniramine	>100,000
PCM	>100.000

6-Monoacethylmorphine	10
Codeine	>100,000
Ethylmorphine	>100,000
Hydrocodone	50,000
Hydromorphone	10,000
Levorphanol	>100,000
Morphine 3-β-D-glucuronide	>100,000
Morphine	100,000
Norcodeine	>100,000
Normorphine	>100,000
Oxycodone	>100,000
Oxymorphone	10,000
Procaine	50,000
Thebaine	10,000
Diacetylmorphine (heroin)	25
Acetylcodeine	>10,000
Buprenorphine	>10,000
Dihydrocodeine	>10,000
Nalorphine	5,000
Dextromethorphan	>100,000
Imipramine	>100,000
Levacetylmethadol (LAAM)	>100,000
Meperidine	>100,000
Methadone	>100,000
Mitragynine (kratom)	>20,000
Morphine 6-D-glucuronide	>100,000
Naloxone	>100,000
Naltrexone	>100,000
Naproxen	>100,000
Norbuprenorphine	>10,000
Norbuprenorphine glucuronide	>100,000
Norhydrocodone	>100,000
Noroxycodone	>100,000
Noroxymorphone	>100,000
Norpropoxyphene	>100,000
Oxymorphone-3 _B -D- glucuronide	>100,000
Tapentadol HCI	>100,000
Tramadol	>100,000

C. Interfering Substances
A study was conducted to determine the interference of the test with the
compounds. The following compounds showed no interference when tester
Multi Drug Uring Toot Dingard at a concentration up to 100 ug/ml

3-Hydroxytyramine	Acetaminopnen
Acetylsalicylic Acid	Albumin (100 mg/dL)
Albuterol sulfate (Proair HFA)	Aminophylline
Aminopyrine	Amoxicillin
Ampicillin	Apomorphine
Aripiprazole	Aspartame
Atomoxetine	Atorvastatin Calcium
Atropine	Azithromycin
Benzilic acid	Benzocaine
Benzoic acid	Bilirubin
Bupropion	Captopril
Carbamazepine	Cefradine
Cephalexin	Chloral Hydrate
Chloramphenicol	Chlorothiazide
Chlorpheniramine	Chlorpromazine
Cholesterol	Ciprofloxacin Hydrochloride
Citalopram	Clarithromycin
Clonidine	Clozapine
Conjugated Estrogens	Cortisone
Cotinine	Creatinine
D,L- Isoproterenol	D,L-Octopamine
D,L-Propranolol	D,L-Tryptophan
D,L-Tyrosine	Deoxycorticosterone
Dextromethorphan	Diclofenac
Diflunisal	Digoxin
Diphenhydramine	Dopamine HCl
D-Pseudoephedrine	Duloxetine
Ecgonine methyl ester	Erythromycin
Esomeprazole Magnesium	Ethanol (1%)
Fenoprofen	Fluoxetine Hydrochloride
Furosemide	Gabapentin
Gentisic Acid	Glucose
Hemoglobin	Hydralazine
Hydrochlorothiazide	Hydrocortisone
Ibuprofen	Isoxsuprine
Ketamine	Ketoprofen
Labetalol	Levofloxacin Hydrochloride
Levonorgestrel	Levothyroxine Sodium
Lidocaine Hydrochloride	Lisinopril
Loperamide	Loratadine
Magnesium Meprobamate	Meperidine Methoxyphenamine (except MET test)

Metoprolol Tartrate	Mifepristone
N-Acetylprocainamide	Nalidixic Acid
Naloxone	Naltrexone
Naproxen	Niacinamide
Nicotine	Nifedipine
Nitroglycerin	Norethindrone
Noscapine	O-Hydroxyhippuric Acid
Omeprazole	Oxalic Acid
Oxolinic Acid	Oxymetazoline
Paliperidone	Papaverine
Penicillin-G	PenicillinV Potassium
Perphenazine (Acetophenetidin)	Phenacetin
Phenelzine	Prednisone
Pregablin	Quinine
Ranitidine	Rifampicin
Risperidone	Salicylic Acid
Serotonin	Sertraline Hydrochloride
Sildenafil Citrate	Simvastatin
Sulfamethazine	Sulindac
Tetrahydrocortisone 3-(β-D-glucuronide)	Tetrahydrocortisone 3-acetate
Tetrahydrozoline	Theophylline
Thiamine	Thioridazine
Tramadol Hydrochloride	Trazodone Hydrochloride
Triamterene	Trifluoperazine
Trimethoprim	Tyramine (except AMP test)
Uric Acid	Venlafaxine HCl
Verapamil	Vitamin B2
Vitamin C (Ascorbic acid)	Zomepirac
β-Estradiol	Acyclovir

D. Effect of Urinary Specific Gravity

The urine samples with different specific gravity ranging from 1.000~1.035 are spiked with the target drug at 25% below and 25% above cutoff level. Each sample was tested by the test device. The results demonstrate that varying ranges of urinary specific gravity do not affect the test result.

E. Effect of Urinary pH

The pH of an aliquot negative urine pool is adjusted to a pH range of 4 to 9 in 1 pH unit increments and spiked with each drug at 25% below and 25% above cutoff levels. Each sample was tested by the test device. The result demonstrates that varying range of pH do not interfere with the performance of the test.

BIBLIOGRAPHY OF SUGGESTED READING

1. Baselt, R.C. Disposition of Toxic Drugs and Chemicals in Man. Biomedical Publications, Davis, CA, 1982.
2. Ellenhorn, M.J. and Barceloux, D. G Medical Toxicology. Elservier Science Publishing Company, Inc., New York, 1988
3. Gilman, A. G., and Goodman, L. S. The Pharmacological Fluids, in Martin WR(ed): Drug Addiction I, New York, Spring – Verlag, 1977.
4. Harvey, R.A., Champe, P.C. Lippincotts Illustrated Reviews. Pharmacology. 91-95, 1992.
5. Hawwks RL, CN Chiang, Urine Testing for drugs of Abuse. National Institute for Drug Abuse (NIDA), Research Monography 73, 1986.
6. Hofmann F.E., A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects, New York, Oxford University Press, 1983.
7. McBay, A. J. Clin. Chem. 33,33B-40B, 1987.

ASSISTANCE Call toll-free (888) 695-5248 (Monday - Friday 9:00 am - 5:00 pm, CST) or email to support@dochekusa.com.

INDEX OF SYMBOL

Consult instructions for use

Keep away from sunlight REF Catalogue number Use-by date LOT (2) Batch code Do not reuse

Keep dry

Manufactured for:

Dochek USA INC
1111 W 35th St Unit 502, Chicago, IL, 60609
Tel: (888) 695-5248
Email: info@dochekusa.com

Do not use if package is damaged

MADE IN CHINA

Doc No.: Ver1.1 GB Rel.: 2024/07/24